Theorem Adds RadMD to its Roster of Strategic Alliances
News Aug 16, 2013
Theorem Clinical Research has announced the addition of RadMD, a cutting-edge medical imaging expertise company, to its roster of strategic alliances.
“These kinds of alliances allow us to extend our capabilities to offer a greater depth and spectrum of services to our clients,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development.
Spurgin continued, “When we work with partners that we already know and trust, we feel our clients get a better end result.”
With the increasing utilization of imaging in clinical research, there has been a greater demand for expertise on the use of medical imaging in clinical trials.
RadMD offers unique services centered solely on the use of imaging in trials. They provide a consultative approach to implementing medical imaging endpoints based on extensive experience in the pharmaceutical development of both diagnostic and therapeutic drugs.
RadMD’s services include expertise in constructing customized medical imaging solutions, a unique worldwide network of more than 600 physicians and medical imaging experts available for independent image evaluations or “blinded reads”, regulatory strategy, imaging endpoint justification and extensive imaging training capabilities.
“We are excited to be able to bring our imaging expertise in clinical development to Theorem’s clientele, and look forward to working together to develop innovative products for our mutual customers and patients,” said Doug Stefanelli RadMD COO and executive vice president.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE